Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study

被引：0
|
作者：
Song, Daniel Y.
George, Saby
Zimberg, Shawn
Nordquist, Luke T.
Tomaszewski, Jeffrey
Conti, Peter S.
Meltzer, Jeffrey
Verholen, Frank
Schmall, Anja
Higano, Celestia S.
Sartor, A. Oliver
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[2] Roswell Park Canc Inst, Buffalo, NY USA
[3] Adv Radiat Ctr New York, Lake Success, NY USA
[4] GU Res Network, Urol Canc Ctr, Omaha, NE USA
[5] MD Anderson Canc Ctr Cooper, Div Urol, Camden, NJ USA
[6] USC, Keck Sch Med, Mol Imaging Ctr, Los Angeles, CA USA
[7] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[8] Bayer Consumer Care, Basel, Switzerland
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[11] Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5050
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy of radium-223 dichloride in castration-resistant metastatic prostate cancer
    Sobrevilla Calvo, Pedro de Jesus
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 26 - 27
  • [42] Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
    Vidal, Monica
    Delgado, Alejandro
    Martinez, Carlos
    Jaime Correa, Jose
    Cristina Durango, Isabel
    INTERNATIONAL BRAZ J UROL, 2020, 46 (04): : 599 - 611
  • [43] The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
    Heinrich, Daniel
    Bektic, Jasmin
    Bergman, Andries M.
    Caffo, Orazio
    Cathomas, Richard
    Chi, Kim N.
    Daugaard, Gedske
    Keizman, Daniel
    Kindblom, Jon
    Kramer, Gero
    Olmos, David
    Omlin, Aurelius
    Sridhar, Srikala S.
    Tucci, Marcello
    van Oort, Inge
    Nilsson, Sten
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E223 - E231
  • [44] Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
    Cha, Tai-Lung
    Wu, Tony Tong-Lin
    Vogelzang, Nicholas John
    Huang, Chao-Yuan
    Huang, Shu-Pin
    Lin, Chia-Chi
    Ou, Yen-Chuan
    Pang, See-Tong
    Shen, Daniel Heung-Yuan
    Wu, Wen-Jeng
    Chang, Wayne Yen-Hwa
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (11) : 825 - 836
  • [45] Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and/or denosumab.
    Cao, Yen Thi Kim Hong
    Trieu, Janson
    Rojas, Vanessa
    Elias, Michael
    Anderson, Michael J.
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer
    Parimi, Sunil
    Bondy, Suraya
    Tsang, Erica
    McKenzie, Michael Ross
    Bachand, Francois
    Aparicio, Maria
    Duncan, Graeme
    Sunderland, Katherine
    Olson, Robert Anton
    Pai, Howard Huaihan
    Alexander, Abraham Skaria
    LaPointe, Vincent
    Chi, Kim N.
    Tyldesley, Scott
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (10): : E311 - E316
  • [47] The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
    Sciuto, Rosa
    Rea, Sandra
    Ungania, Sara
    Testa, Antonella
    Dini, Valentina
    Tabocchini, Maria Antonella
    Patrono, Clarice
    Soriani, Antonella
    Palma, Valentina
    Marconi, Raffaella
    Strigari, Lidia
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [48] Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
    Rahbar, Kambiz
    Essler, Markus
    Eiber, Matthias
    La Fougere, Christian
    Prasad, Vikas
    Fendler, Wolfgang P.
    Rassek, Philipp
    Hasa, Ergela
    Dittmann, Helmut
    Bundschuh, Ralph A.
    Pabst, Kim M.
    Kurtinecz, Milena
    Sandstrom, Per
    Verholen, Frank
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [50] A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345